The Important Part: Investing with Liz Thomas

There are a handful of genuinely useful data points - the FDA shortage mechanism enabling compounding pharmacies, specific Frito-Lay price cuts, and the Shopper Intelligence finding on GLP-1 users shifting to intent-based buying - but the episode is padded with well-worn macro narrative (people eat less, buy activewear, drink less alcohol) that any attentive investor already knows. Personal anecdotes, including a lengthy Frito-Lay dumpster story, bleed significant runtime.

“FDA actually declared a short in somewhere around 2023, 2024. When the FDA declares a shortage. Other drug makers can get into the mix”

“they see this market growing at a 10 to 12% compound annual growth rate for the next 10 years”

The episode rehearses the standard consensus GLP-1 narrative (food companies hurt, athleisure wins, wellness rising) without any contrarian, first-principles, or counterintuitive argument. The compounding-pharmacy mechanism is the one modestly under-covered angle; otherwise the framing is identical to mainstream financial-media coverage from 2023-2024.

“looks maxing, which is really a part of who we are right now on social media”

“one pill makes you smarter, one pill makes you small. Go ask Alice”

Caleb Silver is a legitimate senior media executive (editor-in-chief of Investopedia, chief business editor at Dotdash Meredith) with genuine breadth across verticals, but he is a journalist and trend-tracker, not a practitioner who has operated in pharma, CPG, or retail at scale; his knowledge is observational rather than operational.

“I'm the chief business editor, looking at all of our portfolios”

“we have verywell health and health.com in our portfolio. And what we're hearing from physicians and physician practices is it's a completely different patient”

The episode names specific companies (Empire in Texas, Red Rock in Utah as compounding pharmacies; Hims and Hers; Frito-Lay's 15% price cut; Sabra and Siesta acquisitions; Shopper Intelligence as a data source) and offers a few concrete numbers (1 in 8 Americans, 10-12% CAGR, 80% Lilly/Novo market share, sub-5% grocery margins), which is better than average; however, most claims about behavioral change are asserted anecdotally rather than supported with rigorous data.

“Empire in Texas, Red Rock in Utah. You don't know the compounding companies, you know, the consumer facing companies. Hims and hers”

“Frito Lay announced back in February for the first time...they were going to cut prices up to 15% on their top brands”

The host asks mostly open-ended, leading questions and rarely challenges an assertion; the one genuine follow-up ('But are they as effective?') stands out as an exception. A lengthy personal anecdote about dumpster-diving at a Frito-Lay factory consumes airtime with no informational value, and closing questions like 'So do you sell McDonald's and buy Chipotle?' are simplistic rather than probing.

“But are they as effective?”

“So do you sell McDonald's and sell shake Shackles and buy Chipotle and buy, I don't even know, protein powder makers”